LUNESTA WITHDRAWAL SYMPTOMS
HOW TO SUCCESSFULLY WEAN OFF LUNESTA At Home

LUNESTA ABRUPT DISCONTINUATION SYMPTOMS MAY INCLUDE: 

Abdominal & muscle cramps, vomiting, sweating, shakiness, & rarely, seizures may occur & finally rebound insomnia*

LUNESTA SIDE EFFECTS MAY INCLUDE: 

Drowsiness, dizziness, lightheadedness, difficulty with coordination, memory loss or amnesia, tolerance, dependence, changes in behavior and thinking; such as more outgoing or aggressive behavior than normal, confusion, strange behavior, agitation, hallucinations, worsening of depression, suicidal thoughts*

LUNESTA ADVERSE REACTIONS MAY INCLUDE: per PDR 

Severe: bronchospasm, oliguria, erythema multiforme, peptic ulce, suicidal ideation, angioedem, anaphylactoid reactions 

Moderate: depression, confusion, hallucinations, memory impairment, myasthenia, oral ulceration, urinary incontinence, ataxia, vaginitis, melena, hypertonia, conjunctivitis, dysuria, cholelithiasis, hematuria, hypertension, lymphadenopathy, nystagmus, stomatitis, heat intolerance, anemia, hostility, cystitis, contact dermatitis, hypercholesterolemia, vaginal bleeding, peripheral neuropathy, euphoria, gastritis, hyperlipidemia, hypokalemia, myopathy, hepatomegaly, neuritis, photophobia, colitis, hepatitis, hyperesthesia, iritis, dehydration, phlebitis, hyperacusis, gout, dysphagia, furunculosis, migraine, chest pain (unspecified), peripheral edema, impaired cognition, dyspnea, complex sleep-related behaviors 

Mild: dysgeusia, headache, drowsiness, infection, dizziness, xerostomia, dyspepsia, restlessness, nausea, diarrhea, rash, anxiety, abnormal dreams, vomiting, gynecomastia, dysmenorrhea, libido decrease, increased urinary frequency, fever, laryngitis, insomnia, xerophthalmia, hiccups, amenorrhea, tinnitus, xerosis, epistaxis, vertigo, anorexia, otalgia, skin discoloration, diaphoresis, malaise, weight loss, urticaria, halitosis, acne vulgaris, emotional lability, breast enlargement , muscle cramps, appetite stimulation, alopecia, photosensitivity, weight gain, paresthesias, polydipsia, agitation, menorrhagia, hirsutism, mydriasis, ptosis, tremor, maculopapular rash, dysosmia, somnambulism*

LUNESTA  BOXED WARNINGS: per PDR:

Behavioral changes, CNS depression, coadministration with other CNS depressants, complex sleep-related behaviors, driving or operating machinery, drug-induced complex sleep-related behaviors, ethanol ingestion 

Sedative-hypnotics can cause complex sleep-related behaviors such as phone calls, sexual activity, preparing and eating food, or sleep driving while not fully awake and in some cases having no memory of the event. These behaviors appear to be more frequent with nonbenzodiazepine benzodiazepine-receptor agonists (NBRAs), such as eszopiclone, than other sedative-hypnotics. Although rare, serious injuries or death have occurred; therefore, eszopiclone and other NBRAs are contraindicated in patients with a history of drug-induced complex sleep-related behaviors. Patients should be informed of the risks before receiving any medication from this class, including instructions to discontinue the medication if they experience a sleep-related episode and to contact their healthcare provider immediately. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of NBRAs to the FDA MedWatch Safety Information and Adverse Event Reporting Program.[64083] Because eszopiclone has a rapid onset of action and causes CNS depression, it should only be administered before retiring. Patients should be instructed to avoid driving or operating machinery or performing other tasks requiring mental alertness after taking eszopiclone. Because eszopiclone can cause drowsiness and a decreased level of consciousness, there is a higher risk of falls, particularly in the elderly, with the potential for subsequent severe injuries. A variety of abnormal thinking and behavioral changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., aggressiveness and extroversion that seem out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably. Any emergence of changes in thinking or behavior should be evaluated. Although such behaviors may occur with the use of the drug alone at therapeutic doses, the use of higher doses, or the use of the drug with alcohol or the coadministration with other CNS depressants appears to increase the risks. Advise patients to avoid ethanol ingestion. Eszopiclone can cause next-day psychomotor and memory impairment, with patients often unaware that they are impaired. Results from one study indicate that peak impairment after a 3 mg dose occurs 7.5 hours later, with clinically relevant effects still present at 11.5 hours after the dose. Lower initial dosages of eszopiclone should be considered in patients taking other CNS depressant therapies.*

top of page